Future oncology (London, England)

Keyphrases

Publications

volume 19, number 10, 2023

Christopher H Lieu
Podcast article: Biomarker testing in colorectal cancer. Future oncology (London, England) 19 (10) (2023)
Ibtissam Acem, Veroniek M van Praag, Cassidy Qb Mostert, Robert J P van der Wal, Ralph Ml Neijenhuis, Cornelis Verhoef, Dirk J Grünhagen, Michiel Adreanus van de Sande
Noninvasive detection of soft tissue sarcoma using volatile organic compounds in exhaled breath: a pilot study. Future oncology (London, England) 19 (10) (2023)
Ibtissam Acem, Veroniek M van Praag, Cassidy Qb Mostert, Robert J P van der Wal, Ralph Ml Neijenhuis, Cornelis Verhoef, Dirk J Grünhagen, Michiel Adreanus van de Sande
Noninvasive detection of soft tissue sarcoma using volatile organic compounds in exhaled breath: a pilot study. Future oncology (London, England) 19 (10) (2023)
Seda Kahraman, Enes Erul, Mustafa Seyyar, Ozge Gumusay, Ertugrul Bayram, Burcin Cakan Demirel, Omer Acar, Sercan Aksoy, Naziyet Kose Baytemur, Elif Sahin, Devrim Cabuk, Gul Basaran, Semra Paydaş, Arzu Yaren, Deniz Can Guven, Atike Pinar Erdogan, Umut Demirci, Alper Yasar, İbrahim Vedat Bayoglu, Mutlu Hizal, Burcu Gulbagci, Nail Paksoy, Sena Ece Davarci, Funda Yilmaz, Ozlem Dogan, Sibel Oyucu Orhan, Erkan Kayıkçıoğlu, Ali Aytac, Merve Keskinkilic, Eda Eylemer Mocan, Olcun Umit Unal, Esra Aydin, Hakan Yucel, Deniz Isik, Onder Eren, Basak Oyan Uluc, Melike Ozcelik, Ilhan Hacibekiroglu, Adnan Aydiner, Hacer Demir, Berna Oksuzoglu, Ebru Cilbir, Erdem Cubukcu, Bulent Cetin, Esin Oktay, Cihan Erol, Sadi Kerem Okutur, Nilgun Yildirim, Ali Alkan, Fatih Selcukbiricik, Asude Aksoy, Yusuf Karakas, Gulhan Ozkanli, Berna Bozkurt Duman, Dincer Aydin, Ozgecan Dulgar, Muhammed Muhiddin Er, Fatih Teker, Tugba Yavuzsen, Musa Baris Aykan, Ali Inal, Yakup Iriagac, Nurhan Onal Kalkan, Murat Keser, Teoman Sakalar, Serkan Menekse, Engin Kut, Burak Bilgin, Muge Karaoglanoglu, Veli Sunar, Ozlem Ozdemir, Nazim Serdar Turhal, Nuri Karadurmus, Bulent Yalcin, Mehmet Ali Nahit Sendur
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future oncology (London, England) 19 (10) (2023)

volume 19, number 15, 2023

volume 19, number 16, 2023

Atakan Topcu, İsmail Yurtsever, Zehra Sucuoglu Isleyen, Mehmet Besiroglu, Ayse Irem Yasin, Zeynep Alaca Topcu, Abdallah T M Shbair, Özlem Toluk, Melih Simsek, Mesut Seker, Haci Mehmet Turk
The correlation between skeletal muscle index and anxiety in patients with lung cancer on the first day of chemotherapy. Future oncology (London, England) 19 (16) (2023)

volume 19, number 17, 2023

Chiaki Inagaki, Ryo Matoba, Satoshi Yuki, Manabu Shiozawa, Akihito Tsuji, Eisuke Inoue, Kei Muro, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa
The BEETS (JACCRO CC-18) trial: an observational and translational study of BRAF -mutated metastatic colorectal cancer. Future oncology (London, England) 19 (17) (2023)

volume 19, number 4, 2023

Zekeriya Hannarici, Ali Yılmaz, Mehmet Emin Buyukbayram, Aykut Turhan, Alperen Akansel Çağlar, Mehmet Bilici, Salim Başol Tekin
The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer. Future oncology (London, England) 19 (4) (2023)
Zekeriya Hannarici, Ali Yılmaz, Mehmet Emin Buyukbayram, Aykut Turhan, Alperen Akansel Çağlar, Mehmet Bilici, Salim Başol Tekin
The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer. Future oncology (London, England) 19 (4) (2023)

volume 19, number 6, 2023

Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) 19 (6) (2023)
Patrick Daniele, Carla Mamolo, Joseph C Cappelleri, Timothy Bell, Alexander Neuhof, Gabriel Tremblay, Mihaela Musat, Anna Forsythe
Overall and complete response rates as potential surrogates for overall survival in relapsed/refractory multiple myeloma. Future oncology (London, England) 19 (6) (2023)

volume 19, number 7, 2023

Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Petros Fessas, Bernhard Scheiner, Antonio D'Alessio, Claudia A M Fulgenzi, James Korolewicz, Caroline Ward, Paul Tait, Robert Thomas, Alessio Cortellini, Rohini Sharma, David J Pinato
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. Future oncology (London, England) 19 (7) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Petros Fessas, Bernhard Scheiner, Antonio D'Alessio, Claudia A M Fulgenzi, James Korolewicz, Caroline Ward, Paul Tait, Robert Thomas, Alessio Cortellini, Rohini Sharma, David J Pinato
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. Future oncology (London, England) 19 (7) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Francesca Jackson-Spence, Charlotte Toms, Luke Furtado O'Mahony, Julia Choy, Lucy Flanders, Bernadett Szabados, Thomas Powles
IMvigor011: a study of adjuvant atezolizumab in patients with high-risk MIBC who are ctDNA+ post-surgery. Future oncology (London, England) 19 (7) (2023)
Petros Fessas, Bernhard Scheiner, Antonio D'Alessio, Claudia A M Fulgenzi, James Korolewicz, Caroline Ward, Paul Tait, Robert Thomas, Alessio Cortellini, Rohini Sharma, David J Pinato
PETAL protocol: a phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma. Future oncology (London, England) 19 (7) (2023)

volume 19, number 8, 2023

Sharada Harricharan, Eileen Curran, Huamao Mark Lin, Laura Walton, Khushboo Gurjar, Khoi Nguyen, Anna Forsythe
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future oncology (London, England) 19 (8) (2023)
Tao Zheng, Jiangyang Pan, Dan Du, Xin Liang, Huiling Yi, Juan Du, Shuo Wu, Lanxiang Liu, Gaofeng Shi
Preoperative assessment of high-grade endometrial cancer using a radiomic signature and clinical indicators. Future oncology (London, England) 19 (8) (2023)
Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer. Future oncology (London, England) 19 (8) (2023)
Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer. Future oncology (London, England) 19 (8) (2023)
Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer. Future oncology (London, England) 19 (8) (2023)
Sharada Harricharan, Eileen Curran, Huamao Mark Lin, Laura Walton, Khushboo Gurjar, Khoi Nguyen, Anna Forsythe
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future oncology (London, England) 19 (8) (2023)
Tao Zheng, Jiangyang Pan, Dan Du, Xin Liang, Huiling Yi, Juan Du, Shuo Wu, Lanxiang Liu, Gaofeng Shi
Preoperative assessment of high-grade endometrial cancer using a radiomic signature and clinical indicators. Future oncology (London, England) 19 (8) (2023)
Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer. Future oncology (London, England) 19 (8) (2023)
Rupali Fuldeore, Leonardo Passos Chaves, Qi Feng, Nigel Rozario, David Nimke, Stephanie Braun
Treatment patterns, healthcare resource utilization and costs of HER2-negative gastric/gastroesophageal junction cancer. Future oncology (London, England) 19 (8) (2023)
Sharada Harricharan, Eileen Curran, Huamao Mark Lin, Laura Walton, Khushboo Gurjar, Khoi Nguyen, Anna Forsythe
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future oncology (London, England) 19 (8) (2023)
Sharada Harricharan, Eileen Curran, Huamao Mark Lin, Laura Walton, Khushboo Gurjar, Khoi Nguyen, Anna Forsythe
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future oncology (London, England) 19 (8) (2023)
Tao Zheng, Jiangyang Pan, Dan Du, Xin Liang, Huiling Yi, Juan Du, Shuo Wu, Lanxiang Liu, Gaofeng Shi
Preoperative assessment of high-grade endometrial cancer using a radiomic signature and clinical indicators. Future oncology (London, England) 19 (8) (2023)
Sharada Harricharan, Eileen Curran, Huamao Mark Lin, Laura Walton, Khushboo Gurjar, Khoi Nguyen, Anna Forsythe
Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future oncology (London, England) 19 (8) (2023)

volume 19, number 9, 2023

Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Qianru Zhang, Zhao Bi, Xingguo Song, Yue Zhang, Shiwen Wang, Li Xie, Xian-Rang Song
Tumor-educated platelet SNORA58 , SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer. Future oncology (London, England) 19 (9) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)
Qianru Zhang, Zhao Bi, Xingguo Song, Yue Zhang, Shiwen Wang, Li Xie, Xian-Rang Song
Tumor-educated platelet SNORA58 , SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer. Future oncology (London, England) 19 (9) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Qianru Zhang, Zhao Bi, Xingguo Song, Yue Zhang, Shiwen Wang, Li Xie, Xian-Rang Song
Tumor-educated platelet SNORA58 , SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer. Future oncology (London, England) 19 (9) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Charlotte Louise Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Mieke Van Hemelrijck
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review. Future oncology (London, England) 19 (9) (2023)
Amer M Zeidan, Aristoteles Giagounidis, Mikkael A Sekeres, Zhijian Xiao, Guillermo F Sanz, Marlies Van Hoef, Fei Ma, Sabine Hertle, Valeria Santini
STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2. Future oncology (London, England) 19 (9) (2023)
Qianru Zhang, Zhao Bi, Xingguo Song, Yue Zhang, Shiwen Wang, Li Xie, Xian-Rang Song
Tumor-educated platelet SNORA58 , SNORA68 and SNORD93 as novel diagnostic biomarkers for esophageal cancer. Future oncology (London, England) 19 (9) (2023)
Charlotte Louise Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Mieke Van Hemelrijck
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review. Future oncology (London, England) 19 (9) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Charlotte Louise Moss, Teresa Guerrero-Urbano, Ingrid White, Benjamin Taylor, Rebecca Kristeleit, Ana Montes, Louis Fox, Katharina Beyer, Monika Sztankay, Maria M Ratti, Elena S Sisca, Alexandra Derevianko, Steven MacLennan, Nicholas Wood, Lisa M Wintner, Mieke Van Hemelrijck
Assessing the quality of patient-reported outcome measurements for gynecological cancers: a systematic review. Future oncology (London, England) 19 (9) (2023)
Rita Khoury, Rebecca Ibrahim, Tony Ibrahim, Axel Le Cesne, Tarek Assi
NALIRIFOX in the upfront setting of metastatic pancreatic cancer: can FOLFIRINOX finally be dethroned? Future oncology (London, England) 19 (9) (2023)
Leanne Hamerton, Kelly Gomes, Ronan Fougeray, Emma S Knowles, Marta Vargas Gomes, Ole Hauch, Ash Bullement
A UK cost-effectiveness analysis of trifluridine/tipiracil for heavily pretreated metastatic gastroesophageal cancers. Future oncology (London, England) 19 (9) (2023)